Literature DB >> 8880396

Gene therapy in pediatric oncology.

E Benaim1, B P Sorrentino.   

Abstract

An increased understanding of the molecular mechanisms of cancer and the ability to introduce exogenous genes into mammalian cells has led to the development of oncologic treatment strategies based upon gene transfer. Preclinical animal models have suggested a variety of approaches which are now being tested in pediatric trials. Studies using marker genes to trace cell origin have already generated important information regarding autologous bone marrow transplantation for pediatric cancers. A variety of therapeutic genes are also being clinically tested. Trials are underway to determine if introduction of immunostimulatory genes into cancer cells can be used to enhance host antitumor immunity. Treatment of primary brain tumors with insertion of drug sensitization genes is a promising new therapy that is also being clinically evaluated. Other strategies such as insertion of drug resistance genes into hematopoietic cells, anti-oncogene therapy, and tumor suppressor gene replacement are being tested in adults and may find use in pediatric cancer treatment. Although gene transfer offers promising new approaches for the therapy of pediatric cancer, many technical problems remain which limit efficacy and widespread use. Further basic research in the molecular biology of cancer and in vector development will be required to realize the full potential of gene therapy strategies.

Entities:  

Mesh:

Year:  1996        PMID: 8880396     DOI: 10.1007/bf00173685

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  84 in total

Review 1.  Expression of heterologous sequences in adenoviral vectors.

Authors:  K L Berkner
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

Review 2.  European School of Oncology position paper. Gene therapy for the medical oncologist.

Authors:  M Blaese; T Blankenstein; M Brenner; O Cohen-Haguenauer; B Gansbacher; B Sorrentino; T Velu
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

Review 3.  Use of suicide genes in gene therapy.

Authors:  P Tiberghien
Journal:  J Leukoc Biol       Date:  1994-08       Impact factor: 4.962

4.  Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice.

Authors:  J E Dick; M C Magli; D Huszar; R A Phillips; A Bernstein
Journal:  Cell       Date:  1985-08       Impact factor: 41.582

5.  Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy.

Authors:  F L Moolten
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

6.  Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells.

Authors:  P L Hermonat; N Muzyczka
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

7.  In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats.

Authors:  Z Ram; K W Culver; S Walbridge; R M Blaese; E H Oldfield
Journal:  Cancer Res       Date:  1993-01-01       Impact factor: 12.701

Review 8.  Adeno-associated virus vectors.

Authors:  B J Carter
Journal:  Curr Opin Biotechnol       Date:  1992-10       Impact factor: 9.740

9.  Recombinant adeno-associated virus (rAAV)-mediated expression of a human gamma-globin gene in human progenitor-derived erythroid cells.

Authors:  J L Miller; R E Donahue; S E Sellers; R J Samulski; N S Young; A W Nienhuis
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

10.  Interleukin 7 induces CD4+ T cell-dependent tumor rejection.

Authors:  H Hock; M Dorsch; T Diamantstein; T Blankenstein
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.